Effects of Ca2+ channel antagonists on striatal dopamine and DOPA release, studied by in vivo microdialysis

British Journal of Pharmacology
M OkadaS Kaneko

Abstract

1. To elucidate the mechanisms regulating the release of striatal dopamine and its precursor, 3,4-dihydroxyphenylalanine (DOPA), we determined the effects of various Ca2+ channel antagonists, an N-type Ca2+ channel antagonist, omega-conotoxin GVIA, a P-type Ca2+ channel antagonist, omega-agatoxin IVA, and a Q-type Ca2+ channel antagonist, omega-conotoxin MVIIC, on the basal and Ca2+- and K+-evoked release of striatal dopamine and DOPA, by use of in vivo microdialysis. 2. Omega-conotoxin GVIA strongly inhibited striatal basal dopamine release (IC50 = 0.48 nM), whereas this toxin only weakly modulated basal striatal DOPA release (IC50 = 9.55 nM). Neither omega-agatoxin IVA nor omega-conotoxin MVIIC affected the basal striatal release of dopamine and DOPA. 3. Omega-conotoxin GVIA strongly inhibited Ca2+-evoked striatal dopamine release (IC50 = 0.40 nM), whereas Ca2+-evoked striatal DOPA release only was weakly modulated (IC50 = 10.51 nM). Neither omega-agatoxin IVA nor omega-conotoxin MVIIC affected the Ca2+-evoked release of striatal dopamine and DOPA. 4. Both omega-agatoxin IVA and omega-conotoxin MVIIC inhibited the K+-evoked release of striatal dopamine (IC50 of omega-agatoxin IVA = 2.65 nM; IC50 of omega-conotoxin MVIIC = 12....Continue Reading

References

May 1, 1992·The Journal of the American Board of Family Practice·M A Connelly, E K Fowler
Mar 14, 1991·Nature·R M Mulkey, R S Zucker
Dec 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·K OtaniY Fukushima
Nov 6, 1990·European Journal of Pharmacology·L PaniZ L Rossetti
Jan 1, 1987·Annual Review of Neuroscience·G J AugustineS J Smith
Oct 1, 1988·Trends in Neurosciences·S J Smith, G J Augustine
Dec 1, 1983·Archives of Neurology·C G GoetzH L Klawans
Feb 1, 1995·Trends in Neurosciences·K DunlapT J Turner
Feb 1, 1995·The Journal of Physiology·H A PearsonA C Dolphin
Jan 1, 1995·Advances in Pharmacology·Y MisuY Goshima
Feb 1, 1995·Journal of Neurochemistry·A N BasmaH M Geller
Jan 1, 1994·Annual Review of Biochemistry·B M OliveraM E Adams
Apr 1, 1993·Trends in Pharmacological Sciences·Y Misu, Y Goshima
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T J TurnerK Dunlap
Sep 1, 1995·Neuroscience Research·Y MisuY Goshima
Dec 1, 1995·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Y MisuY Goshima
Nov 1, 1995·Epilepsy Research·M OkadaY Fukushima

❮ Previous
Next ❯

Citations

Feb 1, 2003·Pharmacology & Therapeutics·Yoshimi MisuYoshio Goshima
Jun 27, 2002·Trends in Pharmacological Sciences·Yoshimi MisuTakeaki Miyamae
Jun 23, 2000·Epilepsy Research·K MizunoS Kaneko
Apr 21, 1999·Epilepsy Research·M OkadaS Kaneko
Feb 13, 1999·The European Journal of Neuroscience·M OkadaS Kaneko
Jul 8, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Luke Remage-HealeyBarney A Schlinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.